STOCK TITAN

Purple Biotech Ltd. American Depositary Shares - PPBT STOCK NEWS

Welcome to our dedicated page for Purple Biotech Ltd. American Depositary Shares news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech Ltd. American Depositary Shares stock.

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company based in Rehovot, Israel, dedicated to developing innovative cancer therapies that harness the tumor microenvironment to overcome immune evasion and drug resistance. The company's oncology pipeline includes two main drug candidates, CM24 and NT219, along with a pioneering platform of conditionally-activated tri-specific antibodies.

CM24 is a multi-functional immune checkpoint inhibitor undergoing Phase 2 clinical trials for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study, in collaboration with Bristol Myers Squibb, is evaluating CM24 combined with nivolumab and chemotherapy as a second-line treatment. The primary endpoint is overall survival, with interim results expected by mid-2024 and topline data by the end of the same year.

NT219 is a small molecule dual inhibitor targeting IRS1/2 and STAT3. It has shown promising results in a Phase 1/2 dose escalation study for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A Phase 2 study is planned for NT219 in combination with cetuximab, set to begin in the first half of 2024.

Additionally, Purple Biotech’s tri-specific antibody platform aims to conditionally activate T cells and natural killer (NK) cells within the tumor microenvironment. The platform's lead candidate, IM1240, targets 5T4, a tumor-associated antigen, and is designed to induce a localized immune response while minimizing off-tumor side effects.

Recent financial reports indicate that Purple Biotech has a solid cash runway into the first half of 2025, thanks to strategic funding and partnerships. The company’s research and development expenses have seen a slight increase due to ongoing clinical trials, while selling, general, and administrative expenses have decreased.

For more detailed information and the latest updates, visit Purple Biotech’s website.

Rhea-AI Summary
Purple Biotech Ltd. reports preclinical proof of concept data for its conditionally-activated tri-specific antibody platform, showcasing the contribution of NK cells engager arm and conditionally activated T cell engager. The Cleavable capping technology confines therapeutic activity to the local tumor microenvironment, enhancing the therapeutic window in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
none
-
Rhea-AI Summary
Purple Biotech Ltd. announces significant clinical progress for CM24 and NT219, along with the acquisition of a promising immuno-engagers platform. Financial results show a decrease in operating loss and an increase in finance income, with a cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
-
Rhea-AI Summary
Purple Biotech Ltd. announces positive clinical results for NT219 in combination with cetuximab in the treatment of head and neck cancer. The Phase 1/2 study showed a well-tolerated safety profile, with a 29% Objective Response Rate and 71% Disease Control Rate. NT219 demonstrated anti-tumor activity at higher dose levels, especially in HPV negative patients, supporting further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.89%
Tags
Rhea-AI Summary
Purple Biotech Ltd. announced the establishment of the recommended dose for NT219 with demonstrated anti-tumor activity. The company convened a Scientific Advisory Board focusing on NT219's indication in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Prominent key opinion leaders provided insights on clinical studies for NT219 in combination with cetuximab and potentially a PD1 inhibitor. Purple Biotech is ready to move to the next phase of development with the support of the SAB members.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management clinical trial
-
Rhea-AI Summary
Purple Biotech Ltd. announces the recommended Phase 2 dose for NT219 in combination with cetuximab for the treatment of head and neck cancer. The company reported dose-dependent anti-tumor activity with confirmed partial responses and no dose-limiting toxicities. Detailed clinical results from the dose escalation portion of the study will be presented at the ESMO TAT Congress 2024 in Paris.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
-
Rhea-AI Summary
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) appoints Dr. Yael Margolin, a biotech and pharma expert, as an independent member of the Board of Directors. Dr. Margolin brings 35 years of experience and has served in leadership roles in various healthtech companies. The company also announces the resignation of Mr. Fabien Sebille, the Chief Business Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.18%
Tags
management
Rhea-AI Summary
Purple Biotech Ltd. (PPBT) completes patient enrollment in Phase 2 study of CM24, a multi-functional immune checkpoint inhibitor, for pancreatic cancer treatment. Interim analysis of overall survival expected in 1H 2024 and topline analysis in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
-
Rhea-AI Summary
Purple Biotech Ltd. (PPBT) announced positive results for the NT219 Phase 1/2 study in head and neck cancer, with patient enrollment in the Phase 2 CM24 Pancreatic Cancer trial ahead of schedule. The company's cash runway has been extended to the second half of 2025 through recent financing. Financial results for Q3 2023 show an increase in research and development expenses, with a net loss of $5 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
-
Rhea-AI Summary
Purple Biotech has been granted a new patent in China for maintaining a pharmaceutical composition of NT219 in its active form. The patent protects the method of preventing the conversion of NT219 from its active form to a less active form and supports the maintenance of the active form during manufacturing, storage, and handling. This expands Purple Biotech's patent protection for NT219 in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
Rhea-AI Summary
Purple Biotech closes registered direct offering, raising approximately $5 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags

FAQ

What is the current stock price of Purple Biotech Ltd. American Depositary Shares (PPBT)?

The current stock price of Purple Biotech Ltd. American Depositary Shares (PPBT) is $3.7 as of December 23, 2024.

What is the market cap of Purple Biotech Ltd. American Depositary Shares (PPBT)?

The market cap of Purple Biotech Ltd. American Depositary Shares (PPBT) is approximately 8.4M.

What is Purple Biotech Ltd. focused on?

Purple Biotech Ltd. focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, particularly for cancer treatment.

What are the main drug candidates in Purple Biotech's pipeline?

The main drug candidates are CM24 and NT219. CM24 is an immune checkpoint inhibitor for pancreatic cancer, while NT219 is a dual inhibitor targeting IRS1/2 and STAT3 for head and neck cancer.

What is CM24?

CM24 is a multi-functional immune checkpoint inhibitor currently in Phase 2 clinical trials for treating pancreatic ductal adenocarcinoma (PDAC).

What is NT219?

NT219 is a small molecule dual inhibitor targeting IRS1/2 and STAT3, currently being tested in combination with cetuximab for head and neck cancer.

What is unique about Purple Biotech’s tri-specific antibody platform?

This platform conditionally activates T cells and NK cells within the tumor microenvironment, aiming to induce a strong localized immune response while minimizing off-tumor side effects.

What recent milestones has Purple Biotech achieved?

Recent milestones include completing patient enrollment ahead of schedule for the Phase 2 CM24 study and determining the recommended Phase 2 dose for NT219 in combination with cetuximab.

What are Purple Biotech's financial highlights?

Purple Biotech has a cash runway into the first half of 2025, with increased research and development expenses due to ongoing trials and decreased selling, general, and administrative expenses.

Who are Purple Biotech's key partners?

Purple Biotech collaborates with Bristol Myers Squibb for the Phase 2 clinical trials of CM24.

Where is Purple Biotech headquartered?

Purple Biotech is headquartered in Rehovot, Israel.

Where can I find more information about Purple Biotech?

You can find more information on Purple Biotech’s website at https://purple-biotech.com/.

Purple Biotech Ltd. American Depositary Shares

Nasdaq:PPBT

PPBT Rankings

PPBT Stock Data

8.42M
2.53M
2.87%
9.33%
1.25%
Biotechnology
Healthcare
Link
United States of America
Rehovot